Kornimate/medical-research-clean huggingface dataset:
nmda receptor modulation for the treatment of bipolar i disorder

Conditions: Bipolar I Disorder

Summary: at present, the treatment of bipolar i disorder (bd-i), especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived stress. nmda receptor (nmdar) dysfunction is associated with bd-i, particularly its cognitive impairment and perceived stress. this study aims to examine the efficacy and safety of an nmda enhancer (nmdae) in the treatment of cognitive impairment and perceived stress in the patients with bipolar depression.

bipolar i disorder (bd-i) is a severe brain disorder. at present, the treatment of bd-i, especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived stress. this study aims to examine the efficacy and safety of an nmda enhancer (nmdae) in the treatment of cognitive impairment and perceived stress in the patients with bipolar depression. the subjects are bipolar depression patients. they have been treated for bipolar depression for at least four weeks but remain depressive. participating in this study, they will continue the original treatment, and will be randomized, double-blindly to receive the nmdae or placebo for 8 weeks. we will measure 6 cognitive domains (including 9 cognitive tests) and quality of life at weeks 0 and 8; and assess the perceived stress scale, global assessment of function (gaf), various scales for clinical symptoms, and side effects at weeks 0, 2, 4, 6, and 8. the efficacies of nmdae and placebo will be compared. chi-square (or fisher's exact test) will be used to compare differences of categorical variables and t-test (or mann-whitney test if the distribution is not normal) for continuous variables between treatment groups. mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (gee). all p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.

Eligibility criteria:
inclusion criteria: * are 18 to 65 years of age; * satisfy a dsm-5-tr (american psychiatric association) diagnosis of bd-i, current episode depressed, after treatment of stable (i.e., at least 4 weeks) and adequate treatment of antipsychotic (quetiapine or lurasidone) and/or mood stabilizer; * have a 17-item hamilton depression rating scale (hamd) score ≥18 and a young mania rating scale (ymrs) score ≤7 at baseline; * agree to participate in the study and provide informed consent exclusion criteria: * current substance abuse or history of substance dependence in the past 6 months * history of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study * schizophrenia or other psychotic disorder * moderate-severe suicidal risks * severe cognitive impairment * clinically significant laboratory screening tests (including blood routine, biochemical tests) * pregnancy or lactation; * inability to follow protocol

Keywords: bipolar i disorder bipolar depression nmda
clinical trial of a new device for real-time muscle pressure measurements in patients at risk for acute compartment syndrome

Conditions: Compartment Syndrome Traumatic Lower Extremity; Compartment Syndrome Traumatic Upper Extremity

Summary: compartment syndrome remains a very serious complication of lower extremity trauma and/or procedural cases that involved lower or upper extremity surgery. this condition results in muscle death, chronic pain, infection, and possible amputation. early diagnosis is essential to institute interventions to avoid complications. unfortunately, the subjective pain of the patient remains the mainstay for diagnosis. a method or device is needed that would improve the investigator's ability to diagnose this potentially devastating condition. the purpose of this trial is to evaluate the safety and functionality of my01, an investigational device that allows continuous monitoring of intracompartmental muscle pressure in patients at risk for developing acute compartment syndrome. this is a single centre, non-randomized, non-controlled, unblinded, prospective trial of the my01 device. a cohort of 25 participants will be prospectively enrolled to document the performance of the device.


Eligibility criteria:
inclusion criteria: * adults age 16-65. * fracture of the tibia, foot, forearm, femur, or humerus that is felt by the surgeon to have a reasonable indication that elevated intracompartmental pressure could occur in the patient. * planned admission to hospital (to enable monitoring of compartment pressures) * provision of informed consent to participate. exclusion criteria: * frankly contaminated or infected wounds or fractures. * clinical suspicion of acute compartment syndrome requiring urgent fasciotomy at time of presentation to study center. * current or pre-existing neuropathy in the study limb. * pregnant women.

Keywords: acute compartment syndrome
liver adiposity effects on pediatric statin

Conditions: Cholesterol; Lipidosis

Summary: single center, open-label, prospective investigation to quantify the effects hepatocellular fat has on hepatic statin transport and response in children and adolescents in obese and non-obese children and adolescents 8-21 years of age with normal, wild-type slco1b1 c.521tt genotype that are dosed rosuvastatin


Eligibility criteria:
inclusion criteria: * 8-21 years * ldl cholesterol \>130mg/dl (\>95% percentile) * slco1b1 c.521tt genotype * provide informed permission-assent(\<18 yrs.) or consent (≥18 yrs.) * fasting overnight (\~8 hrs.) * enrolled in cardiology pharmacogenomic repository exclusion criteria: * pregnancy * non-fasting * non-removable metal in body or mri unsafe * currently on statin therapy and unwilling to wash out of statin therapy for at least 4 weeks prior to visit 1 and throughout the duration of the study. * underlying unrepaired congenital or acquired cardiovascular defects or repaired congenital or acquired cardiovascular defects with hemodynamically significant residual disease. * history of underlying or laboratory evidence of underlying intestinal, metabolic, autoimmune, renal disease that can alter rosuvastatin disposition\* (absorption, metabolism, distribution, or clearance) * pharmacotherapy that interacts with statins (oatp1b1 inducers/inhibitors) \* * inability to swallow a tablet * \>5x the age-specific upper limit of normal for ast, alt, total and conjugated bilirubin * diarrhea in the last 24 hours * anything that would exclude a participant from completing an mri, such as pacemakers, claustrophobia, or body habitus (e.g., weight greater than 350 lbs.)
study of oral venetoclax tablets to evaluate adverse events and change in disease activity in participants above 19 years of age with acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia (AML)

Summary: acute myeloid leukemia (aml) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). this study will assess how safe and effective oral venetoclax is in participants with aml . adverse events and change in disease activity will be monitored under routine clinical practice. venetoclax is an approved drug for treatment of acute myeloid leukemia (aml). around 600 participants of age 19 years and above will be enrolled in the study in multiple medical institutions across south korea. participants will receive oral venetoclax tablets as prescribed by their physician in the routine clinical practice. participants will be observed for 7 cycles ( each cycle is 28 days). there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at a hospital or clinic. the effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.


Eligibility criteria:
inclusion criteria: --acute myeloid leukemia (aml) participants who have been prescribed oral venetoclax tablets for the first time according to the approved label. exclusion criteria: * participants with contraindications to venetoclax as listed on the approved local label. * participants receiving venetoclax in clinical trials.

Keywords: acute myeloid leukemia (aml) aml venetoclax venclexta venclyxto cancer
teach back method in individuals with heart failure

Conditions: Heart Failure

Summary: this study will be conducted to determine the effect of the training given to indivuduals with heart failure by teach back method on their symptom control, adherence to treatment and self care behaviours.

i̇ntroduction: at least 40 million individuals worldwide live with heart failure. although it is progressive, heart failure symptoms can be controlled through pharmacological treatment and self-care practices. the aim of heart failure treatment is to improve the quality of life of patients, prolong their lifespan, and prevent the progression of symptoms of the disease and re-admission to the hospital. heart failure guidelines state that patient education and post-discharge follow-up are necessary for successful management of symptoms. purpose:this study will be conducted to determine the effect of the training given to indivuduals with heart failure by teach back method on their symptom control, adherence to treatment and self care behaviours. method:this study will be conducted using a randomized controlled research design. the research sample will consist of 58 with heart failure in the cardiology department of a training and research hospital. research data will be collected using introductory information form, the morsky treatment compliance scale, european heart failure self-care behavior scale-12, heart failure symptom status scale. training and consultancy services based on the teach-back method will be provided to individuals in the training group using the "heart failure training guide" in the form of 3 follow-ups in the cardiology clinic and telephone counseling. telephone interviews were conducted by the researcher in the first week after discharge, it will be held in the first month and 3rd month. in addition, patients will receive counseling by calling the researcher if necessary. after the patients are discharged, they will be called 1 week later, at the end of the 1st month and at the end of the 3rd month, and training will be repeated and counseling will be provided in line with the issues needed. research posttest data will be collected 3 months after discharge.

Eligibility criteria:
inclusion criteria: * individuals diagnosed with heart failure at least 6 months ago * individuals who speak and understand turkish * able to communicate by phone * i̇ndividuals who can read and write * those who gave consent to participate in the research exclusion criteria: * under 18 years old * patients with cognitive dysfunction * those with neuro-psychiatric disease * those who did not consent to participate in the research

Keywords: patient education
hyperthermia as a conservative treatment for carpal tunnel syndrome. a randomized "sham" controlled trial

Conditions: Carpal Tunnel Syndrome

Summary: the purpose of this study is to verify the short-term effects of hyperthermia (ht) in pain relief and in functional impairment in patients affected by mild to moderate idiopathic carpal tunnel syndrome. a single blind randomized sham-controlled trial was performed. a 23 patients were affected by idiopathic cts, 11 of them were affected by bilateral cts. the intervention consists of hyperthermia device treatment, treated for 20 minutes per session, a total of 8 sessions. primary outcome is pain (visual analogic scale).

background: non-surgical treatment is generally administered to patients with mild to moderate symptoms. many of these treatments used heat modality. hyperthermia is a relative recent device which produces deep heating. objective: the purpose of this study is to verify the short-term effects of hyperthermia (ht) in pain relief and in functional impairment in patients affected by mild to moderate idiopathic carpal tunnel syndrome. design: a double blind randomized sham-controlled trial. setting: outpatient physical therapy, institutional clinic. participants: 23 patients were affected by idiopathic cts, 11 of them were affected by bilateral cts. intervention: hyperthermia (ht) device treatment, treated for 20 minutes per session, a total of 8 sessions. measurement: primary outcome is pain (visual analogic scale). secondary outcomes were self-reported pain intensity and physical functioning questionnaire (levine/boston), ultrasonographic (median nerve cross sectional area mncsa) and neurophysiological data.

Eligibility criteria:
inclusion criteria: * bilateral or unilateral mild to moderate carpal tunnel syndrome confirmed by clinical and neurophysiological tests, with no indication to surgical intervention. * all patients were grouped into first, second and third classes according to historic and objective (hi-ob)15 scale of cts and minimum, mild cts according to the neurophysiological classification of padua1 exclusion criteria: * secondary entrapment neuropathies (diabetes, systemic disease) * cancer, pregnancy * electroneurographic and clinical signs of axonal degeneration of the median nerve.
analysis of brain diffusion tensor image in stroke patients

Conditions: Stroke

Summary: this clinical study aims to confirm the characteristics of the functional ansiotropy value according to the individual characteristics of stroke patients by taking brain diffusion tensor images for stroke patients and using the mri. to compare hematologic indicators and neurological function levels of stroke patients at the time of imaging examination with brain diffusion tensor imaging indicators.


Eligibility criteria:
inclusion criteria: 1. adults aged 20 years or older with a history of stroke 2. after hearing a detailed explanation of this study and fully understanding it, the subject or legal representative voluntarily decides to participate and agrees in writing to observe the precautions exclusion criteria: patients who meet one or more of the following cannot participate in the study. 1. those with severe medical conditions such as unstable conditions in the cardiovascular system, digestive system, respiratory system, endocrine system, etc., and those with poor general health 2. in the case of a person with impaired consent, a person without a guardian 3. patients who have devices that may be affected by mri, such as pacemakers, spinal cord stimulators, cochlear implants, vp shunts, and nerve stimulators, inserted into the body 4. other cases where the researcher judges that participation in this study is not suitable (this study is not an interventional study, and patients who are participating in other clinical trials or studies or who have participated in other clinical trials or studies within the past 30 days can also participate in this study.)
plasma metabolic biomarkers for multi-cancer diagnosis

Conditions: Lung Cancer; Breast Cancer; Colorectal Cancer; Thyroid Cancer; Gastric Cancer; Cervical Cancer; Liver Cancer; Pancreatic Cancer; Cholangiocarcinoma; Prostate Cancer; Esophageal Cancer; Ovarian Cancer; Renal Cell Carcinoma

Summary: the aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches. the goal is to construct a plasma metabolite database for multi-cancer patients. simultaneously, we will delve into the exploration and validation of a series of metabolic biomarkers for early multi-cancer diagnosis. the objective is to establish a safer, more convenient, and more sensitive early screening method, thereby providing a reliable scientific foundation and critical evidence for improving the early diagnostic process for individuals at high risk of multi-cancer.

firstly, a wide-targeted metabolomic measurement will be conducted on all samples to identify potential metabolite candidate markers and analyze differences in the metabolic profiles of patients with different types of cancer. additionally, a comprehensive metabolite database specific to cancer patients will be constructed. secondly, samples will be randomly allocated into modeling and testing cohorts. the modeling cohort will be further divided into training and validation sets. bioinformatics methods will be used to conduct an in-depth analysis of a wide range of metabolite information to screen out metabolic marker combinations with high diagnostic efficacy for cancer. ultimately, the testing cohort will be used to validate these metabolic biomarkers, aiming to ensure reliability and stability across different patient populations.

Eligibility criteria:
inclusion criteria: * multi-cancer group: * patients with a confirmed diagnosis based on the clinical "gold standard". * collection of plasma samples prior to treatment. * availability of complete clinical data. * control group: * individuals with no abnormalities in routine physical examinations and relevant clinical tests. * age ≥ 45 years. * availability of complete clinical data. exclusion criteria: * previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection. * coexistence of other systemic tumors. * absence of plasma sample collection before treatment. * pregnancy status. * no clear evidence of histopathological diagnosis (not applicable to the control group based on this criterion). * patients with severe acute infections. * patients with severe anemia. * patients with severe liver or kidney dysfunction. * patients with autoimmune deficiency diseases. * patients with hyperlipidemia. * patients received contrast agent injection before blood draw. * patients with psychiatric disorders.
predicting the risk of failure in patients undergoing radiation therapy for localized prostate cancer

Conditions: Prostate Cancer; Radiation Toxicity

Summary: rationale: gathering information about the gleason score, prostate-specific antigen (psa) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctors predict how patients respond to treatment and help plan the best treatment. purpose: this clinical trial is studying the gleason score, psa level, and cancer stage in predicting outcome in patients who have undergone radiation therapy for localized prostate cancer.

objectives: * evaluate the value of the pre-operative gleason score, prostate-specific antigen level, and clinical stage in predicting the risk of failure and death in patients who have undergone radiotherapy for localized prostate cancer. outline: this is a multicenter study. patient medical records are reviewed to collect data about pre-treatment prostate biopsy, assigned gleason score, prostate-specific antigen level, and radionucleotide bone scan. patients complete a bowel toxicity questionnaire to assess quality of life related to acute and long-term bowel toxicity after radiotherapy.

Eligibility criteria:
disease characteristics: * diagnosis of localized adenocarcinoma of the prostate * has undergone radiotherapy (external beam radiotherapy and/or brachytherapy) with or without hormonal therapy for adenocarcinoma of the prostate in the university of california, san francisco (ucsf) radiation oncology department at san francisco general hospital or veterans administration medical center of san francisco between 1987 and 2006 patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: radiation toxicity recurrent prostate cancer stage iib prostate cancer stage iia prostate cancer stage iii prostate cancer stage i prostate cancer stage iv prostate cancer adenocarcinoma of the prostate
validation of the mutuality scale in patients with osa and their partners

Conditions: Obstructive Sleep Apnea

Summary: main objective of this study is to assess the psychometric characteristics of the mutuality scale both in patients with obstructive sleep apnea syndrome (osas) and in their partners-the association between the mutuality score in osas patients and their adherence to the use of continuous positive airway pressure (cpap) therapy will also be investigated. the results of the study may allow a validation of the mutuality score as an instrument for measuring mutuality between osas patients and their partners.


Eligibility criteria:
osa patients: inclusion criteria: * age 18 years and older exclusion criteria: -

Keywords: obstructive sleep apnea
zinc and green tea extract for community respiratory viral infections

Conditions: Respiratory Viral Infection

Summary: zinc and green tea supplementation have both been independently studied for supporting immune health during cold and flu-like illness in non-hospitalized patients with clinical trials demonstrating promising but inconsistent results. combination therapy may offer an improved effect as the antioxidant compounds found in green tea have been shown to increase cellular zinc concentrations thereby inhibiting viral replication. this study seeks to evaluate the effect of combination supplementation using established doses of zinc and green tea extract on symptom duration and severity from cold and flu-like illness, including covid-19, in adult community patients enrolled in a randomized placebo-controlled trial.


Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male or female, aged 18 years and older 4. ability to take oral medication and be willing to adhere to the prescribed dosing regimen 5. self-reported cold or flu symptoms for \< 72 hours exclusion criteria: 1. pregnant or actively seeking to become pregnant 2. positive for influenza with planned treatment with oseltamivir or baloxavir 3. current or planned treatment with an fda regulated drug (including those under eua) for covid-19 4. chronic liver disease (i.e. baseline liver function tests (lfts) \> 1.5x the upper limit of normal (uln) or established cirrhosis 5. chronic renal failure stage 4 or greater 6. history of kidney stones 7. acute secondary bacterial infection at the time of enrollment 8. requiring hospitalization for any reason at the time of enrollment 9. history of copper or iron deficiency 10. current prescription for quinolone antibiotics, tetracycline antibiotics, or penicillamine at the time of enrollment 11. allergy/intolerance to any of the active ingredients under investigation including zinc citrate, green tea, and ascorbic acid (vitamin c) 12. patients without decision making capacity 13. currently enrolled in another clinical trial for a respiratory viral infection